SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

ZCash is trending as the community discusses its recent price surge and potential as a privacy-focused alternative in the crypto space. Conversations revolve around ZEC's limited supply, comparisons to Bitcoin, and speculation about it reaching new all-time highs, while some traders caution about potential pullbacks and shorting opportunities.

1 dog can change your life

1DOG is gaining attention, particularly within the Phantom Wallet community, with users highlighting its "meme energy" and potential for a significant surge. Discussions revolve around its strong community, accessibility via Phantom Wallet, and comparisons to early DOGE vibes. The coin is seen by some as a potential "moonshot" within the meme coin space on the Solana blockchain.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float, with traders actively discussing its potential for a significant squeeze. The community is highlighting the stock's limited public shares and speculating that any positive catalyst could trigger a substantial price increase. Some traders are pointing to previous instances of similar low-float stocks experiencing massive gains, suggesting MTEX could follow suit.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending amidst mixed sentiment, with some community members highlighting its potential for machine-to-machine transactions, while others express concerns about its value and KYC process; discussions include predictions, mining strategies, and frustrations over exchange listings, revealing a divided community perspective on the crypto's future.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst a volatile crypto market, with a sharp dip sparking debates about market manipulation and the role of large players. The community is weighing the impact of potential ETF approvals against concerns of over-leveraged positions and broader market instability. Discussions also include speculation around geopolitical factors influencing price movements and potential bottom levels.

SPDR Series Trust - SPDR S&P Aerospace & Defense ETF

SPDR S&P Aerospace & Defense ETF

The SPDR S&P Aerospace & Defense ETF ($XAR) is trending amid rising geopolitical tensions and discussion of increased global military spending, potentially signaling further growth for the sector. Community members are actively discussing specific holdings and entry points, while also weighing whether current prices fully reflect future growth. Chart updates highlight the sector's strength, with some noting new highs and breakout potential.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF ($SHLD) is trending as geopolitical tensions and increased global defense spending drive interest in defense technology companies. Community discussions highlight the potential impact of international conflicts and defense agreements on the sector, with some noting significant year-to-date gains and unusual options activity. Investors are also watching how key holdings like Palantir ($PLTR) and Rheinmetall ($RNMBY) influence $SHLD's performance.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending as the community rallies around its potential to reach levels similar to $AERO, a competitor with a significantly larger market cap. Investors are drawn to Hydrex's low market cap and recent partnership news, fueling speculation about substantial near-term growth. The community highlights its presence on the Coinbase developer platform as a bullish signal.

Vanguard Group, Inc. - Vanguard Extended Market Index ETF

Vanguard Extended Market ETF

The Vanguard Extended Market ETF ($VXF) is trending as traders discuss potential dip-buying opportunities in small to mid-cap stocks, particularly as the 10-year Treasury yield fluctuates around the 4.00% level. Community members are analyzing technical indicators like moving averages and LEAPS option strategies to gauge market sentiment and potential ROI. Recent alerts regarding $VXF options and discussions around the Thrift Savings Plan (TSP) S-Fund's performance are also contributing to the increased attention.

Zoracles

Zoracles ($ZORA) is trending as the crypto community debates its potential following a recent listing on Robinhood.  Traders are actively discussing entry and exit points, with some expressing bullish sentiment despite recent market volatility, while others worry about large token unlocks and potential rug pulls.  The coin's connection to a social media app and potential for content monetization are also key discussion points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellectar Biosciences (CLRB) stock tumbled over 17% on Tuesday after the company announced an agreement with several institutional investors to exercise certain existing warrants for gross proceeds of approximately $5.8 million.Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/377/cellectar-biosciences-inc-enters-into-agreements-to-raise">stated</a> that a total of 1.05 million existing warrants were exercised. The company now intends to use the net proceeds for working capital and general corporate purposes in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.The capital raise comes on the heels of Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/376/cellectar-biosciences-announces-european-medicines-agency">announcing</a> that it intends to submit a conditional marketing authorization application to the European Medicines Agency for Iopofosine I 131 as a treatment for refractory Waldenstrom macroglobulinemia in early 2026, following advice from the agency’s Scientific Advice Working Party (SAWP).The company stated that it anticipates European Approval by 2027 and commercial availability of the therapy in the 30 countries represented by the EMA in the same year.“We believe this regulatory success is substantial as it further supports Cellectar’s plans to pursue worldwide approval, including a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) under an accelerated approval pathway,” CEO James Caruso said on Monday, while noting that an NDA submission is contingent upon the company obtaining additional funding to initiate a confirmatory trial.Oppenheimer, which has a ‘Perform rating’ on <a href="https://stocktwits.com/symbol/CLRB">CLRB shares</a>, subsequently noted that the news is a substantial positive catalyst that should bolster the company’s efforts to partner the Iopofosine I 131 program.On Stocktwits, retail sentiment around CLRB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1372/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_11_30_27_AM_png_09a789f2e6.webp" alt="CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1372" height="132"><figcaption>CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the decline in the stock price.<stembedurl>https://stocktwits.com/EvenBetter99/message/631308393</stembedurl>Another user expressed hopes about an impending rally in the shares.<stembedurl>https://stocktwits.com/Slab6/message/631300689</stembedurl>CLRB stock is down 43% this year and approximately 92% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 

Equity

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 


Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

DFAS
Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFAS News

DFASDimensional ETF Trust - Dimensional U.S. Small Cap ETF